Bromfenac
- Generic Name
- Bromfenac
- Brand Names
- Bromday, Bromsite, Prolensa, Xibrom, Yellox
- Drug Type
- Small Molecule
- Chemical Formula
- C15H12BrNO3
- CAS Number
- 91714-94-2
- Unique Ingredient Identifier
- 864P0921DW
- Background
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool for optimizing surgical outcomes. Non-oph...
- Indication
For the treatment of postoperative inflammation in patients who have undergone cataract extraction.
- Associated Conditions
- Eye Pain, Ocular Inflammation
- Associated Therapies
- -
Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 156
- Registration Number
- NCT00704418
- Locations
- 🇺🇸
ISTA Pharmaceuticals, Inc., Irvine, California, United States
Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%
- Conditions
- Interventions
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2009-03-19
- Lead Sponsor
- Bp Consulting, Inc
- Target Recruit Count
- 166
- Registration Number
- NCT00595543
- Locations
- 🇺🇸
Soll Eye Associates, Philadelphia, Pennsylvania, United States
Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase
- First Posted Date
- 2007-08-23
- Last Posted Date
- 2009-02-19
- Lead Sponsor
- Florida Eye Microsurgical Institute
- Target Recruit Count
- 42
- Registration Number
- NCT00520260
- Locations
- 🇺🇸
Florida Eye Microsurgical Institute, Boynton Beach, Florida, United States
Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2013-03-14
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 90
- Registration Number
- NCT00423007
- Locations
- 🇺🇸
ISTA Pharmaceuticals, Inc., Irvine, California, United States
Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2013-03-14
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 527
- Registration Number
- NCT00198445
- Locations
- 🇺🇸
Eye Care of San Diego, San Diego, California, United States
🇺🇸Cornea Consultants, Boston, Massachusetts, United States
🇺🇸Ophthalmic Consultants of Long Island, Rockville Centre, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.